Brainstorm Cell Therapeutics (BCLI) Competitors $0.91 -0.01 (-0.65%) As of 10:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCLI vs. PULM, CVM, ENLV, NAII, PMN, NNVC, BCAB, MURA, ANVS, and ELEVShould you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include Pulmatrix (PULM), CEL-SCI (CVM), Enlivex Therapeutics (ENLV), Natural Alternatives International (NAII), ProMIS Neurosciences (PMN), NanoViricides (NNVC), BioAtla (BCAB), Mural Oncology (MURA), Annovis Bio (ANVS), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Brainstorm Cell Therapeutics vs. Pulmatrix CEL-SCI Enlivex Therapeutics Natural Alternatives International ProMIS Neurosciences NanoViricides BioAtla Mural Oncology Annovis Bio Elevation Oncology Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, community ranking, profitability, media sentiment and institutional ownership. Is BCLI or PULM more profitable? Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity.Company Net Margins Return on Equity Return on Assets Brainstorm Cell TherapeuticsN/A N/A -528.56% Pulmatrix -96.51%-45.97%-30.72% Does the MarketBeat Community prefer BCLI or PULM? Brainstorm Cell Therapeutics received 95 more outperform votes than Pulmatrix when rated by MarketBeat users. Likewise, 59.51% of users gave Brainstorm Cell Therapeutics an outperform vote while only 48.28% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformBrainstorm Cell TherapeuticsOutperform Votes29159.51% Underperform Votes19840.49% PulmatrixOutperform Votes19648.28% Underperform Votes21051.72% Which has more volatility & risk, BCLI or PULM? Brainstorm Cell Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Does the media favor BCLI or PULM? In the previous week, Brainstorm Cell Therapeutics had 1 more articles in the media than Pulmatrix. MarketBeat recorded 1 mentions for Brainstorm Cell Therapeutics and 0 mentions for Pulmatrix. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score. Company Overall Sentiment Brainstorm Cell Therapeutics Neutral Pulmatrix Neutral Do analysts recommend BCLI or PULM? Brainstorm Cell Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 3,182.28%. Given Brainstorm Cell Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Brainstorm Cell Therapeutics is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, BCLI or PULM? Pulmatrix has higher revenue and earnings than Brainstorm Cell Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBrainstorm Cell TherapeuticsN/AN/A-$17.19M-$3.66-0.25Pulmatrix$7.81M3.19-$14.12M-$2.61-2.61 Do insiders and institutionals hold more shares of BCLI or PULM? 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 6.7% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryBrainstorm Cell Therapeutics beats Pulmatrix on 11 of the 16 factors compared between the two stocks. Get Brainstorm Cell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCLI vs. The Competition Export to ExcelMetricBrainstorm Cell TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.84M$2.93B$5.40B$7.70BDividend YieldN/A1.91%5.44%4.32%P/E Ratio-0.1930.4322.1918.33Price / SalesN/A478.74401.45107.05Price / CashN/A168.6838.2034.62Price / Book-0.763.786.834.25Net Income-$17.19M-$72.06M$3.20B$247.51M7 Day Performance4.34%11.17%5.92%6.33%1 Month Performance-36.53%-4.87%-4.20%-3.33%1 Year Performance-88.55%-18.74%17.87%5.15% Brainstorm Cell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCLIBrainstorm Cell Therapeutics3.3353 of 5 stars$0.91-0.7%$30.00+3,182.3%-88.7%$5.96MN/A-0.1940PULMPulmatrixN/A$5.39-0.2%N/A+223.9%$19.67M$7.81M-2.0420CVMCEL-SCIN/A$0.24-21.9%N/A-80.0%$19.16MN/A-0.5043Analyst ForecastHigh Trading VolumeENLVEnlivex Therapeutics3.0701 of 5 stars$0.89-1.3%$10.00+1,028.4%-36.0%$18.97MN/A-0.9070Positive NewsGap UpNAIINatural Alternatives International1.227 of 5 stars$3.04+3.1%N/A-54.1%$18.85M$121.85M-2.36290Gap UpHigh Trading VolumePMNProMIS Neurosciences2.8599 of 5 stars$0.57+2.6%$6.00+944.6%-71.2%$18.78MN/A-5.745Positive NewsGap UpNNVCNanoViricidesN/A$1.19+7.2%N/A+17.4%$18.61MN/A-1.6520BCABBioAtla2.4806 of 5 stars$0.32+4.2%$6.00+1,802.9%-80.6%$18.41M$11M-0.1960News CoverageGap UpMURAMural Oncology2.2209 of 5 stars$1.03flat$13.00+1,162.1%-26.7%$17.75MN/A-0.11119ANVSAnnovis Bio1.4189 of 5 stars$1.24-5.0%$37.00+2,896.0%-87.2%$17.58MN/A-0.283Gap UpELEVElevation Oncology3.0584 of 5 stars$0.29+4.9%$3.39+1,052.4%-90.4%$17.40MN/A-0.3640Upcoming EarningsNews Coverage Related Companies and Tools Related Companies PULM Competitors CVM Competitors ENLV Competitors NAII Competitors PMN Competitors NNVC Competitors BCAB Competitors MURA Competitors ANVS Competitors ELEV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCLI) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCLI Stock Free BCLI Stock Alerts